A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.
Solid Tumors
DRUG: INCB186748|DRUG: Cetuximab|DRUG: GEMNabP|DRUG: mFOLFIRINOX
Number of participants with Dose Limiting Toxicities (DLTs), Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol., Up to 28 days|Number of participants with Treatment-emergent Adverse Events (TEAEs), Defined as adverse events reported for the first time or worsening of a pre-existing event occurring after the first dose of study drug up to 30 days (for INCB186748 as monotherapy and in combination with GEMNabP or mFOLFIRINOX) and 60 days (for INCB186748 in combination with cetuximab) after the last dose of INCB186748., Up to approximately 12 months and 60 days|Number of participants with TEAEs leading to dose modification or discontinuation, Number of participants with TEAEs leading to dose modification or discontinuation., Up to approximately 12 months and 60 days
INCB186748 pharmacokinetic (PK) in Plasma, INCB186748 concentration in plasma., Up to approximately 12 months|Objective Response Rate (ORR), Defined as having a best overall Complete Response (CR) or Partial Response (PR), as determined by the investigator by radiographic disease assessment according to RECIST v1.1., Up to approximately 12 months|Disease Control Response (DCR), Defined as having a best overall response of CR, PR, or Stable Disease (SD) as determined by the investigator by radiographic disease assessment according to RECIST v1.1., Up to approximately 12 months|Duration of Response (DOR), Defined as the time from earliest date of disease response (Completed Response or Partial Response) until earliest date of disease progression as determined by the investigator by radiographic disease assessment according to RECIST v1.1 or death due to any cause if occurring sooner than progression., Up to approximately 12 months
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.